Overview

An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001

Status:
Terminated
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
This is an, open-label, long-term safety extension for patients in North America who have completed the prior istradefylline study 6002-INT-001.
Phase:
Phase 3
Details
Lead Sponsor:
Kyowa Kirin Pharmaceutical Development, Inc.
Kyowa Kirin, Inc.
Treatments:
Istradefylline